Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Moodys
Harvard Business School
Medtronic
Mallinckrodt
Boehringer Ingelheim
AstraZeneca

Last Updated: November 12, 2019

DrugPatentWatch Database Preview

Details for Patent: 7,125,560

See Plans and Pricing

« Back to Dashboard

Which drugs does patent 7,125,560 protect, and when does it expire?

Patent 7,125,560 protects TOPAMAX and TOPAMAX SPRINKLE and is included in one NDA.

Protection for TOPAMAX has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has thirty-nine patent family members in thirty-one countries.

Summary for Patent: 7,125,560
Title:Pharmaceutical composition of topiramate
Abstract:The invention is directed to a pharmaceutical composition of topiramate, an anticonvulsant which is useful for treating epilepsy. More specifically, the present invention provides a solid dosage formulation of topiramate intended primarily for use by pediatric patients, or for patients who have difficulty swallowing tablets. Processes for preparing the pharmaceutical composition are also described.
Inventor(s): Thakur; Madhav S. (North Wales, PA), Kotwal; Pramod M. (Blue Bell, PA), Gibbs; Irwin S. (Huntington Valley, PA)
Assignee: Ortho-McNeil Pharmaceutical, Inc. (Raritan, NJ)
Application Number:10/748,764
Patent Claim Types:
see list of patent claims
Use; Composition;

Drugs Protected by US Patent 7,125,560

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Janssen Pharms TOPAMAX topiramate CAPSULE;ORAL 020844-001 Oct 26, 1998 AB RX Yes No   Start Trial   Start Trial Y   Start Trial
Janssen Pharms TOPAMAX topiramate CAPSULE;ORAL 020844-002 Oct 26, 1998 AB RX Yes Yes   Start Trial   Start Trial Y   Start Trial
Janssen Pharms TOPAMAX SPRINKLE topiramate CAPSULE;ORAL 020844-003 Oct 26, 1998 DISCN No No   Start Trial   Start Trial Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 7,125,560

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 017984   Start Trial
Argentina 048456   Start Trial
Argentina 048457   Start Trial
Austria 246490   Start Trial
Australia 2798999   Start Trial
Australia 763643   Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
Merck
Mallinckrodt
Medtronic
McKinsey
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.